Cargando…
Reduction in Herpes Zoster Antiviral Use Since the Introduction of the Live-Attenuated Zoster Vaccine on Australia’s National Immunisation Program: A Population-Based Study from 1994 to 2019
INTRODUCTION: Zostavax, the live-attenuated vaccine used to prevent herpes zoster (HZ), has been available to individuals aged 70 and 71–79 years (phased catch-up) via Australia’s National Immunisation Program (NIP) since 2016. There are limited data characterising the incidence of HZ at the level o...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925617/ https://www.ncbi.nlm.nih.gov/pubmed/36626109 http://dx.doi.org/10.1007/s40121-022-00749-y |